<DOC>
	<DOCNO>NCT01919749</DOCNO>
	<brief_summary>This study use proteomic genomic profiling analyze tumor tissue see treatment select analysis benefit patient .</brief_summary>
	<brief_title>A Pilot Study Utilizing Proteomic Genomic Profiling Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>To examine impact target therapy breast cancer base upon proteomic genomic profiling use RPMA , IHC analysis , RNA-Seq , Exome sequence PFS GMI .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Understand provide write informed consent HIPAA Authorization prior initiation studyspecific procedure Have life expectancy &gt; 3 month Have diagnosis metastatic breast cancer measurable disease ( RECIST 1.1 ) Have progress ≥ 1 prior chemotherapeutic and/or hormonal regimen advance disease . Have documentation progression ( RECIST 1.1 ) treatment regimen immediately prior enter study Be ≥ 18 year age Have ECOG score 01 Be good medical candidate willing undergo biopsy surgical procedure obtain tissue , may may part patient 's routine care malignancy . The requirement amount tissue require analysis detailed Section 6.2.2 . Have prior regimen ≥ 3 week 5 x halflife drug , whichever short recover side effect ( ≤ grade 1 ) regimen Have adequate organ bone marrow function Female patient childbearing potential must negative pregnancy test agree use least one form contraception study least one month treatment discontinuation . For purpose study , childbearing potential define : female patient postmenopause least one year surgically sterile Male patient must use form barrier contraception approve investigator / treat physician study least one month treatment discontinuation . Have tumor biopsy intend use current study perform 2 month prior analysis Have metastatic lesion accessible biopsy Had &gt; 6 month treatment last line therapy Have interventional cancer therapy conduct biopsy collect prior analysis Have symptomatic CNS metastasis . Patients history CNS metastasis treat whole brain irradiation must stable without symptom 4 week completion treatment , image documentation require , must either steroid stable dose steroid ≥ 2 week prior enrollment Have previous history another malignancy ( cure basal cell carcinoma skin cure insitu carcinoma cervix ) within 5 year study entry Have uncontrolled concurrent illness include , limited , ongoing active serious infection , symptomatic congestive heart failure , unstable angina pectoris , unstable cardiac arrhythmia , psychiatric illness , situation would limit compliance study requirement ability willingly give write informed consent Have know HIV , HBV , HCV infection Are pregnant breastfeed patient patient childbearing potential use adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>breast cancer metastatic</keyword>
	<keyword>molecular profiling</keyword>
	<keyword>sequence</keyword>
	<keyword>profile</keyword>
	<keyword>breast cancer</keyword>
</DOC>